All Access.

Ranger Drug-Coated Balloon now available on a 200cm Monorail Platform

Ranger is the only drug-coated balloon on a 200cm monorail platform.

Designed specifically to treat the SFA, the exchange port placement optimizes pushability while the reinforced catheter increases stability.

The only rapid exchange radial-compatible DCB
The longest radial-compatible DCB with sizes up to 200cm
Built on the best-in-class Sterling™ platform
Optimized for pushability with a longer 35cm exchange port and reinforced catheter

Advancing Patient Care Through Innovation in PAD

Dr. Ramzan Zakir shares how embracing evidence-backed technology and transradial access transforms outcomes in interventional cardiology.

Live Case Recording

Watch as Dr. Ankur Lodha, MD performs a live case with the new, all-access Ranger DCB on a 200cm monorail platform while an expert panel discusses the application of Ranger 200cm to treat PAD in the SFA.

Ranger DCB product details

Ranger DCB has a comprehensive matrix and is compatible with various access sites including pedal access¹.

Ranger matrix	40 mm	60 mm	80 mm	100 mm	120 mm	150 mm	200 mm
4 mm	5 F	5 F	5 F	5 F	5 F	5 F	5 F
5 mm	5 F	5 F	5 F	5 F	5 F	5 F	5 F
6 mm	5 F	5 F	5 F	5 F	5 F	5 F	5 F
7 mm	6 F	6 F	6 F	6 F	6 F	6 F	6 F

Over-the wire catheter with working lengths of 80cm, 90cm, 135cm, 150cm, and NEW Monorail 200cm working length and 35cm exchange length

Contact us

Contact a representative to receive consultation on the new Monorail 200cm.

Contact a representative

Ranger indications, safety, and warnings

Ranger Monorail indications, safety, and warnings

References:

1. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Ranger diameters ≤6mm, testing done with Terumo GLIDESHEATH SLENDER™ 5F.4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.

My account